Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

In this extensive real-world cohort of patients with advanced or metastatic NSCLC harboring RET fusions, we highlight the antitumor efficacy of pralsetinib, particularly when administered in later treatment lines. We also observe the aggressive nature of disease progression, frequent utilization of chemotherapy and antiangiogenic agents as initial subsequent therapies, and limited insight into resistance mechanisms due to infrequent rebiopsy and genomic profiling at progression.

Authors

Institutions

Publication Details

Journal
JTO Clinical and Research Reports
Published
2024-10-17
DOI
https://doi.org/10.1016/j.jtocrr.2024.100743
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

Matthieu Carton, Clémence Basse, E. Giroux-Leprieur, M. Aldea et al.
JTO Clinical and Research Reports
Lung Cancer Treatments and Mutations
article

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

Matthieu Carton, Clémence Basse, E. Giroux-Leprieur, M. Aldea, J. Bennouna, M. Pérol, M. Duruisseaux, V. Gounant, Marie Wislez, Florian Guisier, Julien Mazieres, Vincent Fallet, Christos Chouaid, Francesca Lucibello, Anne-Claire Toffart, Aldo Renault, Nicolas M Girard, Nadia Hegarat
article en

Abstract

In this extensive real-world cohort of patients with advanced or metastatic NSCLC harboring RET fusions, we highlight the antitumor efficacy of pralsetinib, particularly when administered in later treatment lines. We also observe the aggressive nature of disease progression, frequent utilization of chemotherapy and antiangiogenic agents as initial subsequent therapies, and limited insight into resistance mechanisms due to infrequent rebiopsy and genomic profiling at progression.

JTO Clinical and Research ReportsVol. 6(1)
Université Claude Bernard Lyon 1 (FR), Inserm (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris Cité (FR), Université Paris-Saclay (FR), Centre Hospitalier Universitaire de Grenoble (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Toulouse (FR), Sorbonne Université (FR), Hôpital Cochin (FR), Assistance Publique – Hôpitaux de Paris (FR), Hospices Civils de Lyon (FR), Centre Hospitalier De Pau (FR), Centre Léon Bérard (FR), Normandie Université (FR), Laboratoire d'Informatique, du Traitement de l'Information et des Systèmes (FR), Maison de la Simulation (FR), Hôpital Ambroise-Paré (FR), Hôpital Louis Pradel (FR), Institut du Thorax (FR), Hôpital Bichat-Claude-Bernard (FR), Hôpital Foch (FR), Hôpital Intercommunal de Créteil (FR), Hôpital Tenon (FR), Université de Rouen Normandie (FR), Institut Curie (FR)
Roche
Openalex Percentile: Top 67%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.